Bio-Techne (TECH) Current Deferred Revenue (2014 - 2026)

Bio-Techne's Current Deferred Revenue history runs 13 years deep, the most recent figure standing at $40.7 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 26.13% year-over-year to $40.7 million; the TTM figure through Mar 2026 stood at $40.7 million (up 26.13% YoY), while the FY2025 annual figure was $32.6 million, up 7.85% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $40.7 million, up from $31.0 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $40.7 million in Q1 2026, with the low at $21.8 million in Q4 2022.
• The 5-year median for Current Deferred Revenue is $30.1 million (2023), against an average of $28.5 million.
• Peak annual rise in Current Deferred Revenue reached 38.0% in 2023, while the deepest fall reached 3.53% in 2023.
• Bio-Techne's Current Deferred Revenue stood at $21.8 million in 2022, then surged by 38.0% to $30.1 million in 2023, then grew by 1.0% to $30.4 million in 2024, then grew by 2.07% to $31.0 million in 2025, then soared by 31.16% to $40.7 million in 2026.
• Business Quant data shows TECH's Current Deferred Revenue at $40.7 million in Q1 2026, $31.0 million in Q4 2025, and $30.4 million in Q3 2025.